MedTrace Logo

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

NCT06481098 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-05-22

No results posted yet for this study

Summary

This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.

Conditions

Interventions

DRUG

HM15275

HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

DRUG

Placebo of HM15275

A sterile, matching solution supplied in pre-filled syringes.

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-28
Primary Completion
2025-05-02
Completion
2025-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06481098 on ClinicalTrials.gov